AG
ALXN

Algert Global’s Alexion Pharmaceuticals ALXN Stock Holding History

Algert Global’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,830
Closed -$317K – 377
2015
Q1 		$317K Buy
+1,830
New +$331K 0.18% 218

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Algert Global's ALXN Position: Q2 2015 in Review

Algert Global sold out of Alexion Pharmaceuticals (ALXN) in Q2 2015, closing a stake of 1,830 shares — an estimated $317K sold.

Algert Global first reported a position in ALXN in Q1 2015 and held it in 1 quarter. The position peaked at $317K in Q1 2015. 547 funds tracked by Wall St. Rank hold ALXN as of Q2 2015.

  • Algert Global reported no remaining Alexion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Algert Global sold 1,830 Alexion Pharmaceuticals shares in Q2 2015, an estimated $317K.
  • Algert Global first reported a position in Alexion Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Algert Global's Alexion Pharmaceuticals position peaked at $317K in Q1 2015.
  • 547 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2015.

Based on Algert Global's 13F filing for Q2 2015, filed 24 Aug 2015.